N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=54 Navigating Mental Health Treatment for Black Youth
Adolescent Behavior · Suicidal Ideation
Primary: Mental Health Treatment Initiation — 9; 10; 7; 7 Participants
N/A N=25 Impact of VVV Group for Veterans With SMI
Psychotic Disorders · Veterans
Primary: The Psychotic Symptoms Rating Scale (PSYRATS-AH) — 20.9 score on a scale — p=0.60
N/A N=81 Informational Nudge to Improve Heart Failure Prescribing
Heart Failure
Primary: Effectiveness (MRA Prescriptions) — 0; 2; 2; 2 Count of MRA prescriptions Filled
Phase 1 N=16 A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions
Healthy Volunteer · Pharmacokinetics After Oral Intake
Primary: AUC0-t — 9450; 8990 h*ng/ml
N/A N=20 Direct Measurement of Motor Cortical Responses to tDCS
Parkinson Disease
Primary: Change in Primary Motor Cortex Beta-Band Spectral Power During Movement Preparation With Anodal tDCS — 12 log10(µV²/Hz)
N/A N=5 Effects of Smoking State on Decision Making
Behavior
Primary: Effort Based Decision Making — 29.5; 18.3 high effort selections
Phase 3 N=338 Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
Moderate Plaque Psoriasis
Primary: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16 — 12.4; 74.2 Percentage of participants…
Phase 2 N=138 Linezolid Dosing Strategies in Drug-Resistant TB
Tuberculosis, Multidrug-Resistant · Tuberculosis · Tuberculosis, Pulmonary
Primary: Time to 26 Weeks Stable Culture Conversion in Liquid Media — 8; 12 Weeks — p=0.0546
Phase 1 N=9 Opioid Antagonism in Hypogonadotropic Hypogonadism
Hypogonadotropic Hypogonadism · Low Testosterone
Primary: Average Change in Mean Luteinizing Hormone (LH) Value — 1.571 IU/L
N/A N=1,180 Getting to Yes, Michigan! (G2YMI)
COVID-19 Vaccines · COVID-19 Pandemic
Primary: Self-reported COVID-19 Vaccine Uptake — 117; 123 Participants
N/A N=20 Trial to Study Electro-Acupuncture in Subjects With Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Primary: Number of Participants That Complete ≥ 8 EA Treatments of a 10-treatment EA Program — 18 Participants
N/A N=592 Residual Gastric Volume Measured by Ultrasound in Diabetic Surgical Population Versus Non-diabetic Surgical Population.
Diabetes Mellitus
Primary: Residual Gastric Volume — 22.1; 33.1; 40.2 mL — p=<0.05
Phase 1 N=10 Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration
Healthy
Primary: Mean Fluorescence Levels Measured by Spectrofluorometer Probe at Timepoint T0 (Before Metvixia® Application) — 6.41; 6.37; 6.51; 6.38 Nanometer (nm)
N/A N=309 Outreach to Reduce Depression Disparities
Depression
Primary: Number of Participants With Initiation of Formal Depression Treatment — 9; 36 Participants